Research Article

Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines

Volume: 12 Number: 3 December 31, 2022
EN

Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines

Abstract

Objective: Successful cancer treatment still requires the discovery of novel compounds that hold promise for chemotherapeutics. The objective of this study was to examine the effectiveness of a newly synthesized cationic palladium(II) coordination compound that functions via several pathways to provide an efficient therapeutic option for various cancer cells.

Materials and Methods: A new cationic palladium(II) coordination compound, [Pd(L)]Cl2·H2O, denoted as Complex 1, where the ligand L is the compound 6,6'-bis(NH-benzimidazol-2-yl)-2,2'-bipyridine), was synthesized and characterized by the attenuated total reflectance (ATR) - fourier-transform infrared spectroscopy (FT-IR), proton nuclear magnetic resonance (1H NMR), electrospray ionization mass spectrometry (ESI-MS), and carbon-hydrogen-nitrogen (CHN) analyses. The density functional theory (DFT) calculations show the coordination sphere around the metal center in Complex 1 to be made up of tertiary N atoms of the pyridine (py) and benzimidazole (bim) rings completing the square-planar geometry with significant distortion. The anti-growth/cytotoxic activity of the complex was determined using the sulforhodamine B (SRB) and adenosine triphosphate (ATP) viability assays for 24 and 48 h in vitro. The study evaluates the determinations for annexin V-propidium iodide (PI) positivity, mitochondrial membrane potential loss, Bcl-2 protein inactivation, and deoxyribonucleic acid (DNA) damage to investigate the cell death mode and its partial mechanism.

Results: Complex 1 caused cytotoxicity in a dose-dependent manner in all the cell lines used, with IC50 values ranging from 2.6-8.8 μM for 48 h. Among the cancer models, colon and breast cancer cell lines underwent cell death by well-described apoptosis through the intrinsic pathway involving the mitochondria. However, the other cell lines did not show such a cell death modality. This implies that differential cell death modes operate based on the cancer type.

Conclusion: For the treatment of breast and colon cancers, the complex 1 appears to be a unique, promising complex. Therefore, complex 1 deserves further attention for proof of concept in animal models.

Keywords

References

  1. 1. Phillips MC, Mousa SA. Clinical application of nano-targeting for enhancing chemotherapeutic efficacy and safety in cancer management. Nanomedicine 2022; 17(6): 405-21. [CrossRef] google scholar
  2. 2. Racane L, Zlatar I, Perin N, Cindric M, Radovanovic V, Banjanac M, et al. Biological Activity of Newly Synthesized Benzimidazole and Benzothizole 2, 5-Disubstituted Furane Derivatives. Molecules 2021; 26(16): 4935. [CrossRef] google scholar
  3. 3. Roopashree B, Gayathri V, Gopi A, Devaraju KS. Syntheses, characterizations, and antimicrobial activities of binuclear ruthenium (III) complexes containing 2-substituted benzimidazole derivatives. J Coord Chem 2012; 65(22): 4023-40. [CrossRef] google scholar
  4. 4. Renouard T, Fallahpour RA, Nazeeruddin MK, Humphry-Baker R, Gorelsky SI, Lever ABP, et al. Novel ruthenium sensitizers containing functionalized hybrid tetradentate ligands: synthesis, characterization, and INDO/S analysis. Inorg Chem 2002; 41(2): 367-78. [CrossRef] google scholar
  5. 5. Yau HC, Chan HL, Yang M. Determination of mode of interactions between novel drugs and calf thymus DNA by using quartz crystal resonator. Sens Actuators B Chem 2002; 81(2-3): 283-88. [CrossRef] google scholar
  6. 6. Heringova P, Kasparkova J, Brabec V. DNA adducts of antitumor cisplatin preclude telomeric sequences from forming G quadruplexes. J Biol Inorg Chem 2009; 14(6): 959-68. [CrossRef] google scholar
  7. 7. Büyükekşi SI, Orman EB, Şengül A, Altındal A, Özkaya AR. Electrochemical and photovoltaic studies on water soluble triads: Metallosupramolecular self-assembly of ditopic bis (imidazole) perylene diimide with platinum (II)-, and palladium (II)-2, 2': 6', 2 "-terpyridyl complex ions. Dyes Pig 2017; 144: 190-202. [CrossRef] google scholar
  8. 8. Largy E, Hamon F, Rosu F, Gabelica V, De PE, Guédin A, et al. Tridentate N-Donor Palladium (II) Complexes as Efficient Coordinating Quadruplex DNA Binders. Chemistry 2011; 17(47): 13274-283. [CrossRef] google scholar

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Publication Date

December 31, 2022

Submission Date

October 14, 2022

Acceptance Date

December 5, 2022

Published in Issue

Year 2022 Volume: 12 Number: 3

APA
Erkısa Genel, M., Selvi, S., Yılmaz, I., Akar, R. O., Yaylım, İ., Şengül, A., & Ulukaya, E. (2022). Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines. Experimed, 12(3), 188-201. https://doi.org/10.26650/experimed.1188586
AMA
1.Erkısa Genel M, Selvi S, Yılmaz I, et al. Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines. Experimed. 2022;12(3):188-201. doi:10.26650/experimed.1188586
Chicago
Erkısa Genel, Merve, Selin Selvi, Ismail Yılmaz, et al. 2022. “Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound With N4-Tetradentate Hybrid Ligand in Cancer Cell Lines”. Experimed 12 (3): 188-201. https://doi.org/10.26650/experimed.1188586.
EndNote
Erkısa Genel M, Selvi S, Yılmaz I, Akar RO, Yaylım İ, Şengül A, Ulukaya E (December 1, 2022) Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines. Experimed 12 3 188–201.
IEEE
[1]M. Erkısa Genel et al., “Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines”, Experimed, vol. 12, no. 3, pp. 188–201, Dec. 2022, doi: 10.26650/experimed.1188586.
ISNAD
Erkısa Genel, Merve - Selvi, Selin - Yılmaz, Ismail - Akar, Remzi Okan - Yaylım, İlhan - Şengül, Abdurrahman - Ulukaya, Engin. “Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound With N4-Tetradentate Hybrid Ligand in Cancer Cell Lines”. Experimed 12/3 (December 1, 2022): 188-201. https://doi.org/10.26650/experimed.1188586.
JAMA
1.Erkısa Genel M, Selvi S, Yılmaz I, Akar RO, Yaylım İ, Şengül A, Ulukaya E. Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines. Experimed. 2022;12:188–201.
MLA
Erkısa Genel, Merve, et al. “Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound With N4-Tetradentate Hybrid Ligand in Cancer Cell Lines”. Experimed, vol. 12, no. 3, Dec. 2022, pp. 188-01, doi:10.26650/experimed.1188586.
Vancouver
1.Merve Erkısa Genel, Selin Selvi, Ismail Yılmaz, Remzi Okan Akar, İlhan Yaylım, Abdurrahman Şengül, Engin Ulukaya. Differential Cytotoxic Activity of a New Cationic Pd(II) Coordination Compound with N4-Tetradentate Hybrid Ligand in Cancer Cell Lines. Experimed. 2022 Dec. 1;12(3):188-201. doi:10.26650/experimed.1188586